Waltham, MA, United States of America

Kala Pharmaceuticals, Inc.


USPTO Granted Patents = 53

% Expired Patents = 43.4



Trademarks = 1

Forward Citations = 217

Loading Chart...
Loading Chart...

21 inventors (with patents filed for the assignee):

goldMedal Winston Zapanta Ong (46 out of 47 patents)

silverMedal Pawel Wojciech Nowak (30 out of 31 patents)

bronzeMedal Jinsoo Kim (23 out of 23 patents)

4.  Elizabeth M Enlow (19 out of 38 patents)

5.  Minh Ngoc Nguyen (18 out of 18 patents)

6.  Ben C Askew (15 out of 52 patents)

7.  Alexey Popov (9 out of 30 patents)

8.  John Thomas Feutrill (8 out of 8 patents)

9.  Hongming Chen (7 out of 26 patents)

10.  James Bourassa (7 out of 26 patents)

11.  Justin Scot Hanes (5 out of 71 patents)

12.  Colin R Gardner (4 out of 13 patents)

13.  Laura M Ensign (4 out of 20 patents)

14.  Tao Yu (4 out of 13 patents)

15.  Ming Yang (4 out of 16 patents)


Core Competencies:
Therapeutic Compounds
Urea Derivatives
Nanocrystals
Poly(vinyl Alcohol)
Particle Transport
VEGFR2 Inhibitors
Crystalline Forms
Meropenem Derivatives
Biochemical Binding
Functionalized Copolymers
Polymer Compositions
Drug Delivery

53 patents:

Kala Pharmaceuticals, Inc., based in Waltham, MA, specializes in the development of innovative therapeutic compounds aimed at addressing unmet medical needs. The company focuses on advanced pharmaceutical chemistry, leveraging technologies such as urea derivatives and nanocrystals to enhance drug delivery and efficacy. Key areas of research include particle transport mechanisms and the development of crystalline forms of compounds, including VEGFR2 inhibitors and meropenem derivatives, to improve treatment outcomes in various therapeutic areas.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Kala Pharmaceuticals, Inc.
53 Patents

#32 in Waltham, MA

#377 in Massachusetts

#6,661 in US

#13,309 in the World

Waltham, MA (US)
Waltham, MA, United States of America
Forward Citations = 217

21 inventors:

Please report any incorrect information to [email protected]
Loading…